The latest price target for Myriad Genetics (NASDAQ:MYGN) was reported by B of A Securities on December 13, 2024. The analyst firm set a price target for $13.00 expecting MYGN to fall to within 12 months (a possible -3.35% downside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Myriad Genetics (NASDAQ:MYGN) was provided by B of A Securities, and Myriad Genetics maintained their underperform rating.

The last upgrade for Myriad Genetics Inc happened on May 8, 2024 when Leerink Partners raised their price target to $35. Leerink Partners previously had a market perform for Myriad Genetics Inc.

The last downgrade for Myriad Genetics Inc happened on December 9, 2024 when Leerink Partners changed their price target from $30 to $21 for Myriad Genetics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Myriad Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Myriad Genetics was filed on December 13, 2024 so you should expect the next rating to be made available sometime around December 13, 2025.

While ratings are subjective and will change, the latest Myriad Genetics (MYGN) rating was a maintained with a price target of $15.00 to $13.00. The current price Myriad Genetics (MYGN) is trading at is $13.45, which is out of the analyst’s predicted range.